In November 2025, Professor Ken-ichiro Kosai and his team at Kagoshima University initiated Phase 3 physician-led clinical trials for their oncolytic virus "Surv.m-CRA-1," targeting primary malignant bone tumors. This marks a historic milestone as the first gene therapy product developed by Japanese academia to reach Phase 3 trials, and represents the world's second attempt at full regulatory approval for an oncolytic virus therapy.

Understanding Primary Malignant Bone Tumors

Primary malignant bone tumors are cancers originating directly from bone tissue, with approximately 800 new diagnoses annually in Japan, making them rare cancers. Osteosarcoma, the most common type, frequently affects young people aged 10-20, presenting with pain and swelling around the knees or shoulders.

Current standard treatment combines surgery with chemotherapy, but the drugs used were introduced over 30 years ago. Before the 1970s, surgery alone resulted in 5-10% five-year survival rates. The introduction of chemotherapy improved this to 70-80%, yet treatment outcomes have shown little advancement since.

Surv.m-CRA-1's Revolutionary Mechanism

A "Switch" That Only Targets Cancer Cells

Surv.m-CRA-1 is an oncolytic virus developed from adenovirus. Its key innovation lies in the "survivin promoter" mechanism.

Survivin is a molecule highly expressed specifically in nearly all cancer cells, while rarely present in normal cells. When Surv.m-CRA-1 encounters survivin, it activates and begins replicating exclusively within cancer cells, destroying them from inside. New viruses released from destroyed cancer cells then infect surrounding tumor cells, creating a cascading tumor lysis effect.

Since normal cells lack significant survivin expression, the virus cannot replicate in healthy tissue, preventing damage to normal cells. This high selectivity enables powerful anti-cancer effects while minimizing side effects.

Attacking Cancer Stem Cells

More importantly, Surv.m-CRA-1 can target "cancer stem cells."

Cancer stem cells comprise only 0.1-1% of tumor tissue but possess self-renewal capacity and are the primary cause of recurrence and metastasis. Conventional chemotherapy and radiation effectively kill rapidly dividing cancer cells but have limited effect on dormant cancer stem cells. Surviving stem cells eventually reform cancer tissue after treatment.

Survivin, Surv.m-CRA-1's target, increases expression as cancer becomes more malignant. This means the treatment may actually become more effective against treatment-resistant cancer stem cells and advanced cancers, a revolutionary characteristic absent in existing therapies.

Immune System Activation

Oncolytic viruses offer another advantage: immune response stimulation. Cancer antigens released during viral destruction of cancer cells can activate the patient's immune system, potentially attacking cancer cells not directly reached by the virus.

Results from Previous Clinical Trials

Surv.m-CRA-1 completed its first-in-human trial (Phase 1) at Kagoshima University Hospital in April 2020. Subsequent multi-center Phase 2 trials confirmed high safety and efficacy.

Notably, patients who consented to long-term observation showed sustained treatment effects, with some cases demonstrating "bone remodeling," or actual bone regeneration. While bone tumor treatment typically replaces bone defects with artificial materials, natural bone regeneration represented a remarkable outcome.

Phase 1/2 trials for pancreatic cancer also confirmed high safety and meaningful efficacy, suggesting potential applications beyond bone tumors.

Differences from Conventional Treatment

Stagnant Drug Development

Chemotherapy for primary malignant bone tumors still relies on drugs introduced in the 1970s-80s, including methotrexate, doxorubicin, and cisplatin. While these show some effectiveness, no new efficacious drugs have emerged in over 30 years.

Standard Treatment Limitations

Current standard treatment involves neoadjuvant chemotherapy to shrink tumors before wide resection surgery, followed by post-operative chemotherapy. Limb salvage rates have improved to approximately 90%, but prognosis remains poor for cases with distant metastasis at diagnosis or post-treatment recurrence/metastasis.

Surv.m-CRA-1 may offer new options for such refractory cancers and recurrent cases. Its ability to target cancer stem cells provides a fundamentally different approach from existing treatments.

Challenges and Efforts to Overcome Them

Patient Recruitment

Primary malignant bone tumors are rare cancers with limited annual incidence of approximately 800 cases. Achieving statistically significant Phase 3 results requires multi-center cooperation to collect cases. This trial involves Kagoshima University Hospital, National Cancer Center Hospital, Kurume University Hospital, and other institutions.

Administration Route Constraints

Current administration primarily involves direct intratumoral injection under ultrasound or CT guidance, limiting application to surface or imaging-accessible tumors. Future developments may enable systemic administration or combination with other therapies for broader application.

Manufacturing and Supply System

Oncolytic viruses are biological products requiring sophisticated quality control and mass production technology. Currently manufactured at US facilities, establishing stable post-approval supply systems is crucial.

Developer Surv Biopharma has already signed an exclusive licensing deal with Nippon Zoki Pharmaceutical for Japan, aiming for prompt patient access after approval.

Long-term Safety Confirmation

Concerns exist about using viruses therapeutically. However, Surv.m-CRA-1's genetic modifications enhance safety, with no serious adverse events reported in clinical trials to date. Phase 3 trials will accumulate more extensive long-term safety data.

Future Outlook and Expectations

Targeting 2027 Implementation

Phase 3 trials typically require 2-3 years; smooth progress could enable implementation by 2027. Approval would make it the world's first oncolytic virus for primary malignant bone tumors, marking Japan-originated advanced medicine as an international treatment option.

Extension to Other Cancer Types

The Surv.m-CRA series shows promise for cancers beyond bone tumors, as survivin is highly expressed across many cancer types. Efficacy against pancreatic cancer is already confirmed, with potential development for diverse cancer types.

Combination Therapy Potential

Oncolytic viruses may produce synergistic effects when combined with other cancer treatments like immune checkpoint inhibitors. Viral therapy's immune response activation could enhance immunotherapy effectiveness.

Significance for Japanese Cancer Treatment

Japan lags behind the US and Europe in bringing gene therapies to practical use. Surv.m-CRA-1's success could become an important model for driving a domestic research-to-implementation pathway, potentially accelerating advanced medical development.

How is new cancer treatment development progressing in your country? We'd love to hear your experiences and thoughts about access to advanced medical care and clinical trial participation opportunities.